Future directions for the management of ovarian cancer

European Journal of Cancer

Volumn 37, Issue SUPPL. 9, 2001, Pages 19-23

  Kaye, Stanley B ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GLYCOPROTEIN P; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; NAVELBINE; ONXY 015; OS 1774; PACLITAXEL; RAF PROTEIN; RECOMBINANT DNA; TOPOTECAN; TREOSULFAN; UNCLASSIFIED DRUG; VALSPODAR; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VIRUS VECTOR; YTTRIUM 90;

ADENOVIRUS; ADJUVANT CHEMOTHERAPY; ANGIOGENESIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ENDOMETRIUM CANCER; GENE THERAPY; HUMAN; MAINTENANCE THERAPY; METASTASIS; OVARY CANCER; PRIORITY JOURNAL;

EID: 0035672422     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)00331-8     Document Type: Article

References (36)

1. High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: The EORTC-GCCG experience
2. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumour activity and toxicity modification by liposomal encapsulation
3. Oral etoposide is active against platinum-resistant epithelial ovarian cancer
4. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
5. Phase II study of gemcitabine (2′.2-difluorodeoxycytidine) in previously treated ovarian cancer patients
6. Navelbine in advanced ovarian epithelial cancer: A study of the French Oncology Centers
7. Treosulfan als effiziente second-line therpaie beim ovarialkarzinom
8. Epirubicin/paclitaxel/carboplatin vs. paclitaxel/carboplatin in first line treatment of ovarian cancer FIGO Stages IIB to IV. Interim results of an AGO-GINECO Intergroup Phase III trial
9. Gemcitabine, Carboplatin, and Paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO Stages IIB-IV
10. Phase I study of Doxil® (liposomal doxorubicin) in combination with paclitaxel
11. Phase I trial and interaction pharmacokinetics of pegylated-liposomal doxorubicin (Caelyx; Doxil) and weekly taxol
12. Phase I study of Doxil (DOX), paclitaxel (TAX) and cisplatin (CIS) in patients (pts) with advanced solid tumours
13. A phase I study of paclitaxel, carboplatin, and liposomal doxorubicin in ovarian, peritoneal and tubal carcinoma: A Gynecologic Oncology Group study
14. Sequential or alternating doxorubicin and CMF regimen in breast cancer with more than three positive nodes
15. Loss of normal p53 function confers sensitisation to Taxol
16. Cellular responses to DNA damage and cisplatin
17. Paclitaxel/carboplatin followed by topotecan in advanced ovarian cancer, a phase I study
18. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: A Danish Ovarian Study Group trial (DACOVA)
19. A randomized phase III trial of adjuvant intraperitoneal radioimmuno-therapy in ovarian cancer
20. Interim analysis of a double blind study of Ovarex, MAB B43.13 versus placebo in patients with ovarian cancer
21. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer
22. Intervention debulking surgery in advanced epithelial ovarian cancer
23. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
24. Randomized phase 3 study of intravenous (iv) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose iv carboplatin (CARB) followed by iv PAC and intraperitoneal (ip) CIS in optimal residual ovarian cancer (OC): An intergroup trial (GOG, SWOG, ECOG)
25. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of malignant ovarian tumors
26. Phase III randomized trial of high dose chemotherapy and PBSC support in patients with advanced ovarian cancer; preliminary results of a GInECO/FNLCC/Study
27. ONYX-015, an E1B gene-attenuated adenovirus, causes tumour-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
28. Phase I trial of i.p. onyx 015 in patients with recurrent ovarian cancer
29. Phase I trial of Adp53 for ovarian cancer patients
30. Phase I EIA gene therapy inpatients with advanced breast and ovarian cancer
31. Drug resistance factors
32. SDZ PSC 833/paclitaxel in paclitaxel-refractory ovarian carcinoma: A phase II trial with renewed response
33. Phase 2 evaluation of OS1-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian cancer
34. High Raf-1 kinase activity protects human tumour cells against paclitaxel-induced cytotoxicity
35. hMLH1 expression and cellular responses of ovarian tumour cells to cytotoxic agents
36. The role of methylation of the hMLH1 promoter in loss of expression to drug resistance in ovarian cancer